A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis

Completed · Phase 2 · Has a placebo group

Conditions studied: Bronchiectasis

In brief

This study is open to adults with bronchiectasis. People can join the study if they produce sputum and have a history of flare-ups (also called exacerbations). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. Participants are put into 4 groups randomly, which means by chance. Participants in groups 1, 2, and 3 get different doses of BI 1291583. Participants in group 4 get placebo. Placebo tablets look like BI 1291583 tablets, but do not contain any medicine. Participants take the tablets once a day. Participants are in the study for between 6 months and 1 year. During this time, they visit the study site about 10 times and get about 5 phone calls from the site staff. The doctors document when participants experience flare-ups during the study. The time to the first flare-ups is compared between the treatment groups. Doctors also regularly check participants' health and take note of any unwanted effects.

Key facts

Study ID

NCT05238675

Run by

Boehringer Ingelheim

People needed

322

Starts

2022-04-28

Expected to finish

2024-05-30

Last updated by the study team

2026-07-28

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female patients: Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly, as well as one barrier method. A list of contraception methods meeting these criteria is provided in the patient information.
• Men participating in this clinical trial must use male contraception (condom or sexual abstinence) if their sexual partner is a WOCBP.
• Signed and dated written informed consent prior to admission to the study, in accordance with Good Clinical Practice (GCP) and local legislation.
• Age of patients when signing the informed consent ≥18 (for Korea: ≥19) and ≤85 years.
• Clinical history consistent with bronchiectasis (e.g., cough, chronic sputum production and/or recurrent respiratory infections) and investigator confirmed diagnosis of bronchiectasis by computed tomography (CT) scan. Subjects whose past chest radiographic image records are not available will undergo a chest CT scan during Screening. Historical scans must not be older than 5 years.
• History of pulmonary exacerbations requiring antibiotic treatment. In the 12 months before Visit 1, patients must have had either:
• at least 2 exacerbations, or
• at least 1 exacerbation and a St. George´s Respiratory Questionnaire (SGRQ) Symptoms score of >40 at screening visit 1.
• For patients on stable oral or inhaled antibiotics as chronic treatment for bronchiectasis, at least one exacerbation must have occurred since initiation of stable antibiotics.
• Current sputum producers with a history of chronic expectoration who are able to provide a spontaneous (not induced) sputum sample at Screening Visit 1.

You may not qualify if…

• Laboratory and medical examination
• Aspartate Aminotransferase (AST) and / or Alanine Aminotransferase (ALT) >3.0 x upper limit of normal (ULN) at Visit 1, or moderate or severe liver disease (defined by Child-Pugh score B or C hepatic impairment).
• Estimated glomerular filtration rate (eGFR) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula < 30 mL/min at Visit 1.
• An absolute blood neutrophil count <1,000/mm\^3 at Visit 1 (equivalent to <1,000 cells/µL or <109 cells/L).
• Any findings in the medical examination and/or laboratory value assessed at Screening Visit 1 or during screening period, that in the opinion of the investigator may put the patient at risk by participating in the trial.
• Positive serological tests for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection, or known infection status.
• Concomitant diagnosis and therapy
• A current diagnosis of:
• Cystic Fibrosis
• Hypogammaglobulinemia
• Common variable immunodeficiency
• α1-antitrypsin deficiency being treated with augmentation therapy
• Allergic bronchopulmonary aspergillosis being treated or requiring treatment
• Tuberculosis or non-tuberculous mycobacterial infection being treated or requiring treatment according to local guidelines
• Palmoplantar keratosis; or keratoderma climactericum
• Hypothyroidism, myxedema, chronic lymphedema with associated hyperkeratosis of the skin, acrocyanosis. If a subject has hypothyroidism but is treated and compensated, the subject is allowed into the trial
• Psoriasis affecting palms and soles; or body surface area for psoriasis ≥ 10%
• Reactive arthritis (Reiter's syndrome); keratoderma blennorrhagicum
• Pityriasis rubra pilaris
• Atopic dermatitis affecting palms and soles; or body surface area for atopic dermatitis ≥ 10%
• Active extensive verruca vulgaris, as per investigator's discretion
• Active fungal infection of hand and/or feet not adequately treated, or not responsive to antifungal therapy, as per investigator's discretion.
• Any clinically relevant (at the discretion of the investigator) acute respiratory infection within 4 weeks prior Visit 2, or any other acute infection requiring systemic or inhaled anti-infective therapy within 4 weeks prior Visit 2.
• Any evidence of a concomitant disease, such as Papillon-Lefevre Syndrome, relevant pulmonary, gastrointestinal, hepatic, renal, cardiovascular, metabolic, immunological, hormonal disorders, or patients who are immunocompromised with a higher risk of invasive pneumococcal disease or other invasive opportunistic infections (such as histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis), that in the opinion of the investigator, may put the patient at risk by participating in the study.
• Received any live attenuated vaccine within 4 weeks prior to Visit 2.

Where it is running

• Klinikum Konstanz — Konstanz, Germany
• Velocity Clinical Research Germany GmbH — Lübeck, Germany
• Klinikum der Universität München - Campus Innenstadt — München, Germany
• Velocity Clinical Research Germany GmbH — Wiesbaden, Germany
• Univ. Gen. Hosp. of Ioannina — Ioannina, Greece
• Semmelweis University — Budapest, Hungary
• Da Vinci Private Clinic — Pécs, Hungary
• Soroka Univ. Medical Center — Beersheba, Israel
• Lady Davis Carmel Medical Center — Haifa, Israel
• Hadassah Medical Center, Ein-Karem — Jerusalem, Israel
• Phoenix Medical Group — Peoria, Arizona, United States
• Newport Native MD, Inc — Newport Beach, California, United States
• University of California Davis — Sacramento, California, United States
• Central Florida Pulmonary Group — Altamonte Springs, Florida, United States
• Malcom Randall VA Medical Center — Gainesville, Florida, United States
• University of Florida College of Medicine — Jacksonville, Florida, United States
• University of Kansas Medical Center — Kansas City, Kansas, United States
• New York University Langone Medical Center — New York, New York, United States
• NewYork-Presbyterian/Weill Cornell Medical Center — New York, New York, United States
• Southeastern Research Center — Winston-Salem, North Carolina, United States
• University of Cincinnati — Cincinnati, Ohio, United States
• Medical University of South Carolina — Charleston, South Carolina, United States
• Institute for Translational Oncology Research — Greenville, South Carolina, United States
• Metroplex Pulmonary & Sleep Center — McKinney, Texas, United States
• Lungenfachklinik Immenhausen — Immenhausen, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.